These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 20189775)

  • 1. Safety and pharmacokinetics of oseltamivir at standard and high dosages.
    Dutkowski R; Smith JR; Davies BE
    Int J Antimicrob Agents; 2010 May; 35(5):461-7. PubMed ID: 20189775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiviral drugs in influenza: an adjunct to vaccination in some situations.
    Prescrire Int; 2006 Feb; 15(81):21-30. PubMed ID: 16548114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oseltamivir oral suspension and capsules are bioequivalent for the active metabolite in healthy adult volunteers.
    Lennon S; Barrett J; Kirkpatrick C; Rayner C
    Int J Clin Pharmacol Ther; 2009 Aug; 47(8):539-48. PubMed ID: 19640363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, double-blind, parallel studies in healthy adult volunteers.
    Vaughan D; Speed J; Medve R; Andrews JS
    Clin Ther; 2010 Jan; 32(1):146-60. PubMed ID: 20171420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and safety of coadministered oseltamivir and rimantadine in healthy volunteers: an open-label, multiple-dose, randomized, crossover study.
    Cirrincione-Dall G; Brennan BJ; Ballester-Sanchis RM; Navarro MT; Davies BE
    J Clin Pharmacol; 2012 Aug; 52(8):1255-64. PubMed ID: 22039289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Absence of adverse effects of oseltamivir on sleep: a double-blind, randomized study in healthy volunteers in Japan.
    Uchimura N; Kuwahara H; Kumagai Y; Mishima K; Inoue Y; Rayner CR; Toovey S; Davies BE; Hosaka Y; Abe M; Prinssen EP
    Basic Clin Pharmacol Toxicol; 2011 Oct; 109(4):309-14. PubMed ID: 21592308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of oseltamivir in young and very elderly subjects.
    Abe M; Smith J; Urae A; Barrett J; Kinoshita H; Rayner CR
    Ann Pharmacother; 2006 Oct; 40(10):1724-30. PubMed ID: 16940405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Steady-state pharmacokinetics and tolerability of orally administered fampridine sustained-release 10-mg tablets in patients with multiple sclerosis: a 2-week, open-label, follow-up study.
    Vollmer T; Blight AR; Henney HR
    Clin Ther; 2009 Oct; 31(10):2215-23. PubMed ID: 19922892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiviral drugs for influenza.
    Med Lett Drugs Ther; 2008 Dec 15-29; 50(1301-1302):98-9, 104; quiz p following 104. PubMed ID: 19078865
    [No Abstract]   [Full Text] [Related]  

  • 10. Incidence of neuropsychiatric adverse events in influenza patients treated with oseltamivir or no antiviral treatment.
    Smith JR; Sacks S
    Int J Clin Pract; 2009 Apr; 63(4):596-605. PubMed ID: 19335705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and safety of intravenous oseltamivir in infants and children in open-label studies.
    Muñoz FM; Anderson EJ; Deville JG; Clinch B; Kamal MA
    Int J Clin Pharmacol Ther; 2015 Jul; 53(7):531-40. PubMed ID: 26042486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pharmacokinetics and tolerability of oseltamivir suspension in patients on haemodialysis and continuous ambulatory peritoneal dialysis.
    Robson R; Buttimore A; Lynn K; Brewster M; Ward P
    Nephrol Dial Transplant; 2006 Sep; 21(9):2556-62. PubMed ID: 16799169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics of oseltamivir when coadministered with probenecid.
    Rayner CR; Chanu P; Gieschke R; Boak LM; Jonsson EN
    J Clin Pharmacol; 2008 Aug; 48(8):935-47. PubMed ID: 18524996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Possible neuropsychiatric reaction to high-dose oseltamivir during acute 2009 H1N1 influenza A infection.
    Nakamura K; Schwartz BS; Lindegårdh N; Keh C; Guglielmo BJ
    Clin Infect Dis; 2010 Apr; 50(7):e47-9. PubMed ID: 20192728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of inhaled zanamivir in the prevention of influenza in community-dwelling, high-risk adult and adolescent subjects: a 28-day, multicenter, randomized, double-blind, placebo-controlled trial.
    LaForce C; Man CY; Henderson FW; McElhaney JE; Hampel FC; Bettis R; Kudule L; Harris J; Yates P; Tisdale M; Webster A
    Clin Ther; 2007 Aug; 29(8):1579-90; discussion 1577-8. PubMed ID: 17919541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Active metabolite from Tamiflu solution is bioequivalent to that from capsule delivery in healthy volunteers: a cross-over, randomised, open-label study.
    Brewster M; Smith JR; Dutkowski R; Robson R
    Vaccine; 2006 Nov; 24(44-46):6660-3. PubMed ID: 16797800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.
    Poli-Bigelli S; Rodrigues-Pereira J; Carides AD; Julie Ma G; Eldridge K; Hipple A; Evans JK; Horgan KJ; Lawson F;
    Cancer; 2003 Jun; 97(12):3090-8. PubMed ID: 12784346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of high-dose oseltamivir in healthy volunteers.
    Wattanagoon Y; Stepniewska K; Lindegårdh N; Pukrittayakamee S; Silachamroon U; Piyaphanee W; Singtoroj T; Hanpithakpong W; Davies G; Tarning J; Pongtavornpinyo W; Fukuda C; Singhasivanon P; Day NP; White NJ
    Antimicrob Agents Chemother; 2009 Mar; 53(3):945-52. PubMed ID: 19104028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oseltamivir prophylactic regimens prevent H5N1 influenza morbidity and mortality in a ferret model.
    Boltz DA; Rehg JE; McClaren J; Webster RG; Govorkova EA
    J Infect Dis; 2008 May; 197(9):1315-23. PubMed ID: 18422444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
    Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
    Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.